Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K on April 2, 2026. The report discloses a significant regulatory milestone regarding its lead drug candidate.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the U.S. Food and Drug Administration (FDA) granting Fast Track designation to the Company's oral, direct-acting protease inhibitor, CDI-988. This candidate is the first oral antiviral being developed for the treatment and prophylaxis of norovirus infection.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the FDA designation. The filing explicitly states that the information in Item 7.01 and the accompanying press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific financial guidance or new risk factors are detailed in this text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the Fast Track designation criteria and next steps.
- Confirm the clinical development status of CDI-988 in recent quarterly reports (10-Q) or annual reports (10-K).
- Review the Company's cash position and burn rate in the most recent financial statements to assess runway for continued development.
- Monitor subsequent filings for any updates on clinical trial timelines or regulatory interactions.